Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Continue Discussions on Elderly Use of Prevenar 13 under National Vaccination Program
A vaccine evaluation panel of the health ministry agreed on July 28 to continue deliberating on whether to add Pfizer’s Prevenar 13, a pneumococcal 13-valent conjugate vaccine, to the publicly funded immunization program for use in the elderly by comparing…
To read the full story
Related Article
- Tailwind for Prevenar 13? Vaccine Panel Members Up for Its Use in High-Risk Elderly
September 11, 2018
- MHLW Panel Snubs 10-Valent Synflorix for Public Immunization Program
May 12, 2016
- Vaccine Panel Wary about Including Synflorix in Public Immunization Program
March 16, 2016
- MHLW to Carefully Discuss Cost Effectiveness of Prevenar 13 for Its Elderly Use under National Program
December 18, 2015
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…